Vetigenics

Vetigenics was proud to sponsor the K9 Talent Show at Marty’s Place Senior Dog Sanctuary’s Howl-O-Ween Family Fest this past weekend! It was a wonderful event for an incredible cause, and we were thrilled to see such a great turnout. A special shout-out to our very own Adriann Sax, who had the tough job of judging the impressive K9 talent. Thanks to everyone who made this event such a success! #supportingseniordogs #howloween #vetigenics #martysplaceseniordogsanctuary #dogs #k9talent

??? Thrilled to announce that Dr. Nicola Mason, one of our founders, is featured in Episode 19 of the Veterinary Cancer Pioneers Podcast! In this episode, Dr. Mason shares her insights on the advancements in veterinary oncology and immunotherapy from her work at the University of Pennsylvania. She discusses leading the first canine cancer immunotherapy consortium supported by the Cancer Moonshot Initiative and the exciting potential of new therapies for both dogs and humans. Her pioneering research and commitment to improving cancer treatment for pets resonate with our mission at Vetigenics. We proudly support her groundbreaking work, which not only enhances veterinary medicine but also contributes to significant advancements in cancer research. Tune in to discover how Dr. Mason is shaping the future of veterinary science! https://lnkd.in/eEFUxD6N

?? Opportunity for Dogs with Urothelial Carcinoma?? Do you know a dog with Urothelial Carcinoma, the most common type of bladder cancer in dogs? We’re offering a unique chance to participate in a pilot clinical trial evaluating VGS-002, a fully canine anti-PD1 antibody designed to enhance anti-tumor immunity. This trial is a no-cost opportunity for dogs diagnosed with this challenging condition and aims to assess the safety and effectiveness of a promising new treatment. ?? Why Participate? - Free access to an innovative investigational therapy. - Contribute to advancements in veterinary medicine and potentially improve your dog's quality of life. If you’re a veterinarian with patients who might benefit or know a dog owner who could be interested, please visit the links below for more information and to inquire about enrollment. Help make a difference in canine cancer treatment! Ethos Vet Clinical Study (https://lnkd.in/ghnjxAhA) or Vetigenics Pipeline & Clinical Trials (https://lnkd.in/epURyPzM) #VetMedicine #ClinicalTrial #DogCancer #Vetigenics #BladderCancer #VeterinaryImmunotherapy #antibody #immunotherapy #dogs #trial #WA #CO #CA #TCC #UrothelialCarcinoma

??Join Us in Supporting Marty’s Place Senior Dog Sanctuary ?? Vetigenics will be sponsoring the K9 Talent Contest at an upcoming event hosted by Marty’s Place Senior Dog Sanctuary! Marty’s Place provides a loving home and care for senior dogs, and we’re honored to be part of this heartwarming event. ??? Enjoy a full day of fun with music, food trucks, vendors, a craft beer & wine garden, and K9-friendly activities like hay rides, agility demos, and more. Plus, exciting raffles with amazing prizes! ?? ?? Date: Saturday October 19th, 2024 ?? Location: 118 Route 526, Allentown, NJ 08501 Whether you’re there for the K9 Talent Contest or the entire event lineup, there’s something for everyone. If you can’t attend, consider supporting Marty’s Place by leanring more about their mission and how they help senior dogs live their best lives. Check out the event flyers for more details (below). We hope to see you there! Together, we can make a difference in the lives of these amazing senior dogs. ???? #DogLovers #SeniorDogs #MartysPlace #K9TalentShow #CommunitySupport #PetHealth #AnimalWelfare #Vetigenics #howloween #Dog #Contest #NJ

?? Spotlight on Dr. Don Siegel: Shaping the Future of CAR-T Therapy?? We’re excited to spotlight Dr. Don Siegel, one of the founders of Vetigenics and a director of the Clinical Cell and Vaccine Production Facility, Center for Advanced Cellular Therapeutics, at University of Pennsylvania Perelman School of Medicine. In a recent article, Dr. Siegel shares his insights on the incredible progress of CAR-T therapy and what’s next for this groundbreaking technology. In addition to his remarkable contributions to human medicine, Dr. Siegel is also contributing to advancing the field of veterinary immunotherapy. Alongside our founder Dr. Nicola Mason, he’s been instrumental in developing innovative treatments for canine cancers and autoimmune diseases. This work is a testament to our commitment to bringing cutting-edge therapies to both pets and people. Discover more about Dr. Siegel’s journey and his impact on both human and veterinary medicine: https://lnkd.in/e-GefYeS #CAR-T #Innovation #MedicalResearch #Immunotherapy #Vetigenics #Leadership #VeterinaryMedicine

We're excited to share insights from our CEO, president, and co-founder, Adriann Sax, featured in PharmaVoice! Vetigenics is at the forefront of developing targeted antibody therapies for pets, addressing the critical need for more accessible and effective treatments for cancer and other chronic diseases. Our innovative approach leverages successful human immunotherapy targets to create species-specific treatments for dogs and cats, making treatments more affordable and easier to administer. With our lead products in pilot trials, we are committed to enabling pets to live their best lives. Learn more about our journey and vision! Read the full article here: https://lnkd.in/eJqx5_rc #AnimalHealth #VeterinaryMedicine #CancerResearch #Biotech #PetHealth #antibody #Vetigenics #immunotherapy #mAbs #monoclonals #dogs

Every year, millions of dogs face a cancer diagnosis, yet effective treatment options remain limited. ???? Repurposed human chemotherapies are often toxic and costly, leaving pet owners with tough choices and less-than-ideal outcomes. Vetigenics, an animal health biopharma firm, wants to change this. By developing targeted antibody therapies that are more affordable and can be administered by general vets, they hope to enhance the quality of life for our furry friends. Their lead products, anti-CTLA-4 and anti-PD-1 antibodies are currently in clinical trials for canine cancers. The company is targeting regulatory approval for both by 2027. Picture is of my beautiful mini labradoodle Maisie, who is thankfully very healthy! #healthcareinnovation #animalhealth #innovation

?? Celebrating Excellence in Canine Health! ?? We are thrilled to announce that one of our founders, Dr. Nicola Mason, has been awarded the prestigious International Canine Health Award at the Kennel Club Charitable Trust's 12th International Canine Health Awards 2024 ceremony last week. Dr. Mason's dedication and groundbreaking work in canine health has made significant strides in improving the lives of our furry friends. Her passion and commitment to veterinary science continue to inspire us all at Vetigenics. As a co-founder, Dr. Mason's vision and leadership have been instrumental in driving our mission forward. Join us in congratulating Dr. Mason on this well-deserved recognition! ?? To read more about the award recipients, click below: https://lnkd.in/eJVuJ7Vy #VeterinaryScience #CanineHealth #AwardWinner #Vetigenics #AnimalHealth #Innovation

?? Exciting update from Vetigenics! ?? Our pilot clinical trial for VGS-002, a fully canine anti-cPD1 monoclonal antibody, is making strides in the fight against canine bladder cancer. With the first dogs already treated, we're eager to enroll more patients and continue this groundbreaking research. Learn more about our innovative approach and its potential impact on canine health. ???? Visit?https://lnkd.in/epURyPzM?or contact?[email protected]?to learn more about enrolling today! #Vetigenics?#CanineCancer?#Immunotherapy?#AnimalHealth?#Innovation?#Antibody?#monoclonal?#mAb?#dogs?#cancer?#canine?#bladdercancer?#translationalmedicine

We are excited to report that the first two dogs with bladder cancer have now received Vetigenics’ fully canine anti-cPD1 monoclonal antibody, VGS-002 in a pilot clinical trial conducted by Ethos Vet. This study is fully funded and is currently recruiting patients. VGS-002 boosts anti-tumor T cell (immune cell) responses that aim to control or eliminate tumor burden. VGS-002 is the canine version of an anti-PD1 immunotherapy that’s demonstrated tremendous success in treating a subset of human patients afflicted with different cancer types. Learn more about this innovative study and participating: https://lnkd.in/ghnjxAhA?#CanineHealth #ClinicalTrial #Vetigenics #immunotherapy #bladdercancer #antibodies #mabs #doghealth #dog